

XVI CURSO EN AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES



B


Vigo, January 28 and 29, 2022

COVID-19 Pandemic Update: The Omicron wave!

Dr. José M^a Miró

Infectious Diseases Service Hospital Clinic - IDIBAPS University of Barcelona Barcelona (Spain)







In Wuhan, China started the outbreak of a novel Coronavirus (COVID-19) in Dec. 2019



Normile D. Science. Jan. 3, 2020 , 10:35 AM

Widespread rapid dissemination in our hyper-connected world creates real-time challenges to prediction analyses













2020-2021


















2020-202? ... Omicron!












COVID-19 Pandemic Update: The Omicron wave!

Current epidemiology

- Virological characteristics
- Diagnosis
- Clinical manifestations and disease severity
- Efficacy of antivirals and anti-inflammatory drugs
- Vaccines efficacy and boosters
- Take-home messages


January 28th 2022

COVID-19 Global Cases




https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6; accessed on January 27th 2022

Global COVID-19: Almost 8,000 daily deaths!




https://www.ft.com/content/a2901ce8-5eb7-4633-b89c-cbdf5b386938?shareType=nongift – January 27th 2022

SARS-CoV-2 VoC in the World: Omicron will replace them!




Kupferschmidt K. Science, Aug 20th 2021; 373:844-849.

The Omicron variant was detected in southern Africa in Nov. 2021, and predominates in South Africa and Botswana




The New York Times. December 13th 2021.

The Omicron variant (B.1.1.529) is much more transmissible than the previous variants of concern (Beta, Delta) !!!




https://timmermanreport.com/2021/11/omicron-variant-the-latest-twist-in-the-pandemic/; November 26th 2021; Burki TK. Lancer Respir Med. Dec 17, 2021

The Omicron variant was detected in southern Africa in Nov. 2021 and has been already detected in ≈100 countries = New Global Wave




https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html; December 27th 2021.

Omicron variant (R₀= 10): Highly transmissible! More than Chickenpox and closer to Measles



https://www.nytimes.com; https://www.nature.com/articles/d41586-021-02259-2; Liu Y et al,. J Travel Med. Oct 11 2021; Burki TK. Lancer Respir Med; Dec 17, 2021


South Africa's huge Omicron wave appears to be decreasing just as quickly as it grew!



Omicron wave appears to be decreasing just as quickly as it grew also in USA!



https://www.nytimes.com/live/2021/12/30/world/omicron-covid-vaccinetests?campaign_id=154&emc=edit_cb_20211230&instance_id=49063&%E2%80%A6. Dec 31, 2021




COVID-19 Pandemic Update: The Omicron wave!

- Current epidemiology
- Virological characteristics
- Diagnosis
- Clinical manifestations and disease severity
- Efficacy of antivirals and anti-inflammatory drugs
- Vaccines efficacy and boosters
- Take-home messages


January 28th 2022

SARS-CoV-2 global phylogeny highlighting the new Omicron lineage



Planas D. Ho D et al. Nature. December 23, 2021.

Omicron (B.1.1.529) variant has lineages: BA.1 and BA.2



https://github.com/cov-lineages/pango-designation/issues/361; https://outbreak.info/situation-reports?pango=BA.1; accessed Dec 27 2021; https://outbreak.info/situation-reports?pango=BA.2; accessed Dec 27 2021.

The Omicron variant (B.1.1.529) has more than 50 mutations, 36 in the Spike protein

Understanding omicron's many mutations

The virus's spikes have far more changes than we've seen in any previous variant, and researchers are racing to figure out how they affect it — and us




Number of mutations identified in each variant's spike, date of earliest documented sample

https://www.washingtonpost.com/health/2021/12/16/omicron-variant-mutations-covid Dec 16th 2021; https://github.com/cov-lineages/pango-designation/issues/361; https://outbreak.info/situation-reports?pango=BA.1; accessed Dec 27 2021; https://outbreak.info/situation-reports?pango=BA.2; accessed Dec 27 2021.

The Omicron variant (B.1.1.529) has more than 50 mutations, 36 in the Spike protein







https://timmermanreport.com/2021/11/omicron-variant-the-latest-twist-in-the-pandemic/; November 26th 2021; and https://www.washingtonpost.com/health/2021/12/16/omicron-variant-mutations-covid Dec 16th 2021; https://www.washingtonpost.com/health/2021/12/16/omicron-variant-mutations-covid Dec 16th 2021; https://outbreak.info/situation-reports?pango=BA.1; accessed Dec 27 2021; https://outbreak.info/situation-reports?pango=BA.2; accessed Dec 27 2021; https://outbre

The Omicron variant (B.1.1.529) Mutations in the receptor binding domain (RBD)

A key to transmissibility: the receptor binding domain




Multiple RBD (including **E484A**) and NTD mutations (and deletion 69/70 in BA.1 lineage; Lack of S gene amplification by the TaqPath method of Thermofisher) are associated with resistance to neutralizing antibodies and therapeutic monoclonal antibodies




https://timmermanreport.com/2021/11/omicron-variant-the-latest-twist-in-the-pandemic/; November 26th 2021; and https://www.washingtonpost.com/health/2021/12/16/omicron-variant-mutations-covid Dec 16th 2021; https://outbreak.info/situation-reports?pango=BA.1; accessed Dec 27 2021; https://outbreak.info/situation-reports?pango=BA.2; accessed Dec 27 2021; https://outbreak.info/situation-reports?

The Omicron variant (B.1.1.529) Mutations in the N-terminal domain (NTD)

A key to immunity: the N-terminal domain




Multiple RBD (including **E484A**) and NTD mutations (and deletion 69/70 in BA.1 lineage; Lack of S gene amplification by the TaqPath method of Thermofisher) are associated with resistance to neutralizing antibodies and therapeutic monoclonal antibodies



https://timmermanreport.com/2021/11/omicron-variant-the-latest-twist-in-the-pandemic/; November 26th 2021; and https://www.washingtonpost.com/health/2021/12/16/omicron-variant-mutations-covid Dec 16th 2021; https://github.com/cov-lineages/pango-designation/issues/361; https://outbreak.info/situation-reports?pango=BA.1; accessed Dec 27 2021; https://outbreak.info/situation-reports?pango=BA.2; accessed Dec 27 2021; h

The Omicron variant (B.1.1.529) Mutations in the Furin cleavage site (FCS)




https://timmermanreport.com/2021/11/omicron-variant-the-latest-twist-in-the-pandemic/; Nov. 26^m 2021; and https://www.washingtonpost.com/health/2021/12/16/omicron-variant-mutations-covid Dec 16th 2021; De Wit Nature Rev Microbiol, 2016; Fung S et al. Annu Rev Microbiol. 2019. 73:529–57; Zhou P et al, Nature, 2020; Yan R et al. Science. 2020; Meng T et al. bioRxiv. doi.org/10.1101/2020.02.08.926006; https://github.com/cov-lineages/pango-designation/issues/361; https://outbreak.info/situation-reports?pango=BA.1; accessed Dec 27 2021; https://outbreak.info/situation-reports?pango=BA.2; accessed Dec 27 2021

The Omicron variant (B.1.1.529) Other Spike and Nucleocapsid mutations


- Spike Q498R and N501Y, also seen in other variants, increase affinity ACE2 receptor (Zahradnik et al., 2021).
- Spike NSP6 deletion (△105-107), similar to deletion to Alpha, Beta, Gamma, Lambda, may be associated with evasion of innate immunity (interferon antagonism) and could also enhance transmissibility (Benvenuto et al., 2021).
- Nucleocapsid R203K + G204R mutations, also seen in Alpha, Gamma and Lambda variants, are associated with increase the expression of subgenomic RNA (Leary et al., 2020) and increase of viral load and increase infectivity (Mourier et al., 2020).

https://timmermanreport.com/2021/11/omicron-variant-the-latest-twist-in-the-pandemic/; November 26th 2021; and https://www.washingtonpost.com/health/2021/12/16/omicron-variant-mutations-covid Dec 16th 2021; https://outbreak.info/situation-reports?pango=BA.1; accessed Dec 27 2021; https://outbreak.info/situation-reports?pango=BA.2; accessed Dec 27 2021; https://outbreak.info/situation-reports?

Cryo-EM structure of the Omicron spike protein-ACE2 complex



Manar D et al. bioRxiv preprint December 21, 2021; Cameroni E et al. Nature. December 23, 2021




COVID-19 Pandemic Update: The Omicron wave!

- Current epidemiology
- Virological characteristics
- Diagnosis
- Clinical manifestations and disease severity
- Efficacy of antivirals and anti-inflammatory drugs
- Vaccines efficacy and boosters
- Take-home messages

January 28th 2022

Timelines for optimal use of different diagnostic tests for COVID-19 detection and host response



Peeling RW et al. Lancet. Dec. 20th 2021; *Bergwerk M et al. N Engl J Med Oct 14th 2021;385:1474-84

Antigen RDT performance against Omicron is OK

- Antigen detection RDT detect the nucleocapsid (N) protein of SARS-CoV-2 (not the Spike [S] protein). Omicron's nucleocapsid protein has a single unique mutational difference from other SARS-CoV-2 variants, a deletion at aa31-33, that does not affect diagnostic performance.
- The UKHSA performed an study evaluating these five lateral flow devices for RDT using different dilutions: Acon Flow Flex 'self-test'; Innova Biotime 'self-test and professional use test'; Orient Gene 'self-test'; SureScreen 'professional use test'; SureScreen 'self-test'
- Performance was optimal and similar to Delta variant with no false negative assay results.




Table 2: Laboratory testing results for the sensitivity of 5 lateral flow devices (in or near deployment) for Omicron (contrived samples, sourced from UK patients Passage 2)

epioyment, for o	nent) for Officion (contrived samples, sourced from or patients Passage 2)						
LFD / Date	Variant	Dilution	Viral titre FFU/ml	Viral Copy number	Number of samples tested	Number of negative results	Number of positive results
Acon Flowflex	Omicron	1/80	1250	4,070,000	5	0	5
09/12/2021		1/800	125	280,000	5	0	5
		1/8,000	12.5	30,000	5	0	5
	Wild type	-	100	460,000	15	0	15
Innova Biotime	Omicron	1/80	1250	4,070,000	5	0	5
09/12/2021		1/800	125	280,000	5	0	5
		1/8,000	12.5	30,000	5	0	5
	Wild- type	-	100	290,000	15	1	14
Orientgene	Omicron	1/80	1250	4,070,000	5	0	5
09/12/2021		1/800	125	280,000	5	0	5
		1/8,000	12.5	30,000	5	0	. 5
	Wild- type	-	100	290,000	15	0	15
SureScreen Professional Test	Omicron	1/80	1250	4,070,000	5	0	5
09/12/2021		1/800	125	280,000	5	0	5
		1/8,000	12.5	30,000	5	0	5
	Wild- type	-	100	580,000	15	0	15
SureScreen Self Test	Live Omicron	1/80	1250	4,070,000	5	0	5
09/12/2021		1/800	125	280,000	5	0	5
		1/8,000	12.5	30,000	5	0	5
	Wild- type	-	100	560,000	15	0	15

UKHSA. Technical briefing #32. December 17, 2021

RT-PCR commercial assays against Omicron = OK

• Amplification of several SARS-CoV-2 genes by RT-PCR (2-3 genes)

- ORF1a, ORF1b, S, E, M and/or N genes
- Lack of S gene amplification (SGTF) by the Thermo Fisher TaqPath assay is key!

Commercial or in-house assay	Spike gene amino acid substitution	Methodology	References
TIB MolBiol	S371L/S373P	Melting curve	[15,16]
TIB MolBiol	ins214EPE	Melting curve	[15,16]
TIB MolBiol	E484A	Melting curve	[15,16]
Thermo Fisher TaqPath	ΔH69/V70	SGTF	[20]
Seegene	E484A, N501Y, ΔH69/V70	RT-PCR	[21]
JRC	Multiple targets	RT-PCR - currently being validated	[18]
Israel Ministry of Health Central Virology Laboratory (CVL) and Israel Institute for Biological Research (IIBR)	nsp6 (Orf1a)	RT-PCR assay – as of 16 December 2021	[10]
University Hospital Geneva	Two partial S gene regions	RT-PCR and Sanger sequencing	[22]
Smorodintsev Research Institute of Influenza (St. Petersburg, Russia)	ORF1 deletion	RT-PCR	[23]
SSI, Denmark	Omicron specific 4-target PCR	RT-PCR	[19]

Table 2. List of available assays/protocols for identification of SARS-CoV-2 Omicron variant (not exhaustive)

https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-characterisation-of-SARS-CoV-2-variants-first-update.pdf


RT-PCR commercial assays against Omicron = OK

			Targ	ets				Reported impact of VOC on signal detection of the S-gen target		
Supplier in Switzerland and Liechtenstein	Test-kit	ORF1ab	RdRp	s	E	м	N	Alpha (B.1.1.7)	Omicron (B.1.1.529)	
Abbott	Abbott RealTime SARS-CoV-2 (#09N77-095)	0	1	0	0	0	1	No S-gene target	No S-gene target	
Abbott	ALINITY m SARS-COV-2 ASSAY (#09N78-095)	0	1	0	0	0	1	No S-gene target	No S-gene target	
Altona	Altona "RealStar® SARS-CoV-2 RT-PCR" (#821005)	0	0	1	1	0	0	No impact	No impact	
Axon Lab / Cepheid	Gene Xpert® Xpress SARS-CoV-2 (#12039255)	0	0	0	1	0	1	No S-gene target	No S-gene target	
Axon Lab	BioGX SARS-CoV-2 kit (#444213)	D	0	0	0	0	2	No S-gene target	No S-gene target	
Axon Lab	EASY® SARS-CoV-2 Kit (#RT020)	D	1	0	0	0	1	No S-gene target	No S-gene target	
Axon Lab	Hi-PCR [®] Coronavirus (SARS-CoV-2) Probe PCR Kit (#MBPCR242)	0	1	0	0	0	0	No S-gene target	No S-gene target	
Axon Lab	NaGene Multiple Real-Time PCR kit for Detection of 2019-nCoV	1	0	0	0	0	1	No S-gene target	No S-gene target	
Axon Lab	Progenie Coronavirus 2019-nCoV Assay (#CORO-UX 5.2)	D	0	0	0	0	1	No S-gene target	No S-gene target	
Becton Dickinson	ViaSure SARS-CoV-2 (N1+N2) Real Time PCR (#444215)	0 0	0	0	0	0	2	No S-gene target	No S-gene target	
Becton Dickinson	ViaSure SARS-CoV-2 S gene Real Time PCR (#444212)*	0	0	1	0	0	0	Detection compromised*	Not available in EU/CHE*	
Becton Dickinson	ViaSure SARS-CoV-2, Flu (A+B) & RSV Real Time PCR Detection Kit (#444217)	D	0	0	0	0	2	No S-gene target	No S-gene target	
bioMerieux	BIOFIRE® COVID-19 test (#423744)	1	0	0	0	0	0	No S-gene target	No S-gene target	
bioMerieux	BIOFIRE® FILMARRAY® Respiratory Panel 2.1+ (RP2.1+) (#423740)	0	0	1	0	1	0	No impact	No impact	
bioMerieux	SARS-COV-2 R-GENE® (#423720)	D	1	0	1	0	1	No S-gene target	No S-gene target	
Bühlmann	Seegene Allplex™ 2019-nCov (#RP10243X) (older Kit)	0	1	0	1	0	1	No S-gene target	No S-gene target	
Bühlmann	Seegene Allplex™ SARS-CoV-2 (#RV10248X) (newer kit)	0	1	1	1	0	1	2x 1-mer mismatch**	No impact	
Bühlmann	Seegene Allplex™ SARS-CoV-2/Flu A/Flu B/RSV Assay (#RV10259X)	D	1	1	0	0	1	1x 1-mer mismatch**	Mismatch (delayed Ct/drop out possible)	
DiaSorin	Simplexa [™] COVID-19 Direct (#MOL4150)	1	0	1	0	0	0	No impact	No impact	
Ender diagnostics	Ender MASS	1	0	0	0	0	0	No S-gene target	No S-gene target	
Hologic	Panther® Fusion SARS-CoV-2 (#AW-21159-001)	2	0	0	0	0	0	No S-gene target	No S-gene target	
Hologic	Aptima® SARS-CoV-2 Assay (#PRD-06419)	2	0	0	0	0	0	No S-gene target	No S-gene target	
Hyris	SARS-CoV-2 human diagnostics (#bKTH-SCV2.02)	0	0	0	0	0	2	No S-gene target	No S-gene target	
FRIZ Biochem	COVID-19 direct RT-PCR (#FBC101)	D	0	0	1	0	1	No S-gene target	No S-gene target	
Lubioscience	2019-nCoV CDC EUA Kit (#10006606)	0	0	0	0	0	2	No S-gene target	No S-gene target	
Mikrogen Diagnostik	ampliCube Coronavirus SARS-CoV-2 (#50143, #50144)	1	0	0	1	0	0	No S-gene target	No S-gene target	
Qiagen	QiaStat-Dx Respiratory SARS-CoV-2 Panel (#691223)	0	1	0	1	0	0	No S-gene target	No S-gene target	
Qiagen	NeuMoDx SARS-CoV-2 Assay (#300800)	1	0	0	0	0	1	No S-gene target	No S-gene target	
Qiagen	SARS-CoV-2 N1+N2 Assay Kit (#222015 or #222017)	0	0	0	0	0	2	No S-gene target	No S-gene target	
Roche Diagnostics	cobas® 6800/8800 SARS-CoV-2 (#09175431190)	1	0	0	1	0	0	No S-gene target	No S-gene target	
Roche Diagnostics	cobas® 6800/8800 SARS-CoV-2 & Influenza A/B (#09233474190)	1	0	0	1	0	0	No S-gene target	No S-gene target	
Roche Diagnostics	cobas® Liat SARS-CoV-2 & Influenza A/B (#09211101190)	1	0	0	0	0	1	No S-gene target	No S-gene target	
Sansure	Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (#S3104E)	1	0	0	0	0	1	No S-gene target	No S-gene target	
Siemens Healthineers	FTD SARS-CoV-2 qPCR Test (#11416302)	1	0	0	0	0	1	No S-gene target	No S-gene target	
TECOmedical	PathoFinder RealAccurate [®] Quadruplex SARS-CoV-2 PCR Kit (#PF0971C-R)	0	1	0	0	0	1	No S-gene target	No S-gene target	
TECOmedical	Eurobio Scientific EurobioPlex SARS-CoV-2 Multiplex (#EBX-041- 192)	D	2	0	0	0	1	No S-gene target	No S-gene target	
Thermo Fisher	TaqPath™ COVID-19 Combo Kit (#A48067)	1	0	1	0	0	1	S-gene drop out	S-gene drop out	
Thermo Fisher	TaqPath [™] COVID-19, FluA/B, RSV (#A49867)	D	0	1	0	0	1	No impact	No impact	
TibMolBio	LightMix [®] Modular Sarbecovirus SARS-CoV-2 (#50-0776-96)	0	1	0	1	0	1	No S-gene target	No S-gene target	

- The most frequently used SARS-CoV-2 PCR tests target many genomic loci, including the the N gene (N = 32), ORF1ab region (N = 16), the RdRp gene (N = 13), the E gene (N = 11), the S gene (N = 8), and, in one case, the M gene (N=1).
- Only two of the eight assays targeting the S gene appear to show S-gene dropout with the Omicron variant (Thermo Fisher TaqPath).
- Given the many SNPs localized on the sequence encoding for the S protein, and concentrated on the RBD in particular, it is likely that some of the serology assays utilizing the wildtype S protein may exhibit decreased sensitivity.


Metzger CMJA et al. Swiss Med Wkly. 2021 Dec 10;151:w30120.

Workflow for Screening and Confirmation of the SARS-CoV-2 Omicron variant



"Surveillance" indicates the routine workflow for how Omicron variants could be detected by the sequencing surveillance program coordinated via CRIVE and the FOPH.
 "Targeted" indicates a suspected case of an Omicron variant which should be confirmed via sequencing.

Metzger CMJA et al. Swiss Med Wkly. 2021 Dec 10;151:w30120.



COVID-19 Pandemic Update: The Omicron wave!

- Current epidemiology
- Virological characteristics
- Diagnosis
- Clinical manifestations and disease severity
- Efficacy of antivirals and anti-inflammatory drugs
- Vaccines efficacy and boosters
- Take-home messages

January 28th 2022


What are the clinical manifestations of Omicron?

- **Shorter incubation period** (2-3 days *vs.* 4-6 days in other variants)
- More or less similar clinical manifestations. Subtle differences.
- Preliminary data from South Africa: Scratchy or sore throat along with nasal congestion, a dry cough and muscle pain, especially low back pain. Omicron causes less loss of taste and smell than other variants (48%/41% vs. 23%/12%, respectively).
- Clinical manifestations can vary depending on whether people are vaccinated (headaches, body aches and fever) or not (flu-like syndrome).

→ **Reinfections**, 9-10% (Alpha and Delta variants previous infections)


https://www.nytimes.com/2021/12/21/well/live/omicron-variant-symptoms-covid.html, Accessed Dec 21, 2021

Cases of Omicron in England by age and sex as of 12 December 2021



UKHSA. Technical briefing #32. December 17, 2021

Secondary Attack Rates higher with Omicron



UKHSA. Technical briefing #33. December 23, 2021

The Omicron variant (B.1.1.529) may be milder than the previous variants of concern (Beta, Delta) in South Africa!



*Rates per 1,000 admissions

https://www.nytimes.com/2021/12/14/world/africa/omicron-south-africa-study.html; December 14th 2021; Dyer O. BMJ December 16th 2021; 375 doi: https://doi.org/10.1136/bmj.n3104

The Omicron variant (B.1.1.529) may be milder than the previous variants of concern (Beta, Delta) in South Africa!

	No. (%) of patients				
	Wave 1 ^a	Wave 2	Wave 3	Wave 4	<i>P</i> value
COVID-19 patients treated	3875	4632	6342	2351	
COVID-19 patients admitted	2628 (67.8)	3198 (69.0)	4400 (69.3)	971 (41.3)	<.001
Age, median (IQR), y	53 (21.75)	54 (21)	59 (24)	36 (32)	<.001
Sex, female/male	1337/1291	1657/1541	2035/2365	590/381	<.001
Patients with comorbidities ^b	1472 (56.0)	1868 (58.4)	2311 (52.5)	227 (23.3)	<.001
Acute respiratory condition on admission	1909 (72.6)	2783 (87.0)	4013 (91.2)	307 (31.6)	<.001
Vaccination status ^c					
Vaccinated				235 (24.2)	
Not vaccinated	No vaccine available	No vaccine available	No register available	645 (66.4)	
Vaccination status unknown			available	91 (9.4)	

Maslo C et al. JAMA Dec. 30 2021

The Omicron variant (B.1.1.529) may be milder than the previous variants of concern (Beta, Delta) in South Africa!

	No. (%) of patients				
	Wave 1 (n = 2628)	Wave 2 (n = 3198)	Wave 3 (n = 4400)	Wave 4 ^b (n = 971)	<i>P</i> value
Receiving oxygen therapy	2119 (80.3)	2624 (82.0)	3260 (74.0)	171 (17.6)	<.001
Receiving mechanical ventilation	431 (16.4)	259 (8.0)	548 (12.4)	16 (1.6)	<.001
Admission to intensive care	1104 (42)	1172 (36.6)	1318 (29.9)	180 (18.5)	<.001
Length of stay, median (IQR), d	8.0 (9)	7.8 (8)	7 (9)	3 (3)	<.001
Deaths	520 (19.7)	790 (25.5)	1284 (29.1)	27 (2.7)	<.001

The hospitalization rates caused by Omicron variant (B.1.1.529) in UK seems to be similar to Delta

Hospitalization Rates Nov. 29 to Dec 11, 2021

Variants


- Delta (N=207,555)
- Omicron (N=1,392)

2.8% 1.7%*

*Admission RR 0.95 (0.61-1.47)


Ferguson et al. Dec. 2021

Omicron replicates much more in the bronchi than the Delta variant but much less than Wuhan in the lung




https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection Dec 15 2021 Kozlov M. Nature. January 13, 2022

Proposed model for Omicron's altered entry pathway leading to more rapid replication in the nasal epithelium



Omicron shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry

Peacock TP et al. bioRxiv preprint January 3, 2022 doi: https://doi.org/10.1101/2021.12.31.474653.



COVID-19 Pandemic Update: The Omicron wave!

- Current epidemiology
- Virological characteristics
- Diagnosis
- Clinical manifestations and disease severity
- Efficacy of antivirals and anti-inflammatory drugs
- Vaccines efficacy and boosters
- Take-home messages

January 28th 2022



Disease stages

Treatment

- Early antiviral therapy - Proper timing anti-inflammatory drugs - Prophylactic heparin


Community	Hospital - Ward	Hospital - ICU		
Asymptomatic/Mild Stages 1-2	Moderate/Severe Stages 3-5	Critical (MV, ECMO) Stages 6-7		
Isolation, at least 10-14 days				
Symptomatic treatment Close monitoring for early				
detection of progression. In older and high risk persons consider: - Parenteral mAbs* (OPAT)	Remdesivir , IV, 5 days Stages 4 (no oxygen) & 5 (low-flow oxygen supply) Stage 6 plus Baricitinib/Tofacitinib , oral, 14 days			
 Molnupiravir, oral 5-d Nirmatrelvir/rtv, oral 5-d Remdesivir (OPAT), IV 3-d 	Parenteral mAbs , single dose Only in seronegative persons			
	Dexamethasone, I Stages 5-7, low/high-flow oxyg Tocilizumab, single	en supply, MV and ECMO		
n. December 2021. experience in vaccinated patients.	Low molecular wei During the entire hospitalization	•		

Dr. JM Miro, personal opinion.

* Seronegative persons. No ex

Activity of antiviral drugs against Omicron

SARS-CoV-2 life cycle: Antiviral targets




can act on various parts of the lifecycle from potentially degrading viral RNA (OAS, RNASL) to inhibiting virus egress (BST-2)

De Wit Nature Rev Microbiol, 2016; Sanders JM, et al. JAMA. 2020 Apr 13. doi: 10.1001/jama.2020.6019.

Antivirals remain active against Omicron!

Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium



https://twitter.com/neyts_johan/status/1470887399341412361 Dec 16 2021; https://www.nytimes.com/article/omicron-coronavirus-variant.html Dec 16 2021; Vangeel L et al. bioRxiv preprint January 15, 2022 doi: https://doi.org/10.1101/2021.12.27.474275

Remdesivir - Outpatient COVID-19 Treatment Trial

- Phase 3 (GS-US-540-9012) double-blind, randomized, placebo-controlled trial compared the efficacy and safety of 3 days of remdesivir (N=279) to standard of care (N=283) in non-hospitalized, high-risk participants with confirmed COVID-19
- 562 participants were randomly assigned 1:1 to receive intravenous (IV) RDV (200 mg on day 1, 100 mg on days 2 to 3) or placebo.
- The primary efficacy endpoint was composite COVID-19 hospitalization or all-cause death by day 28.
- Overall, 52% were male, 44% were Hispanic/Latino ethnicity and 30% were ≥ 60 years old. The most common comorbidities were diabetes mellitus (62%), obesity (56%; median BMI, 30.7) and hypertension (48%).

	Remdesivir N=279	Placebo N=283	<i>P</i> -value
- Hospitalization/all-cause death	0.7%	5.3%	0.008
 Medical visits/all-cause death 	1.6%	8.3%	0.002
- Grade ≥3 TRAEs	3.6%	7.1%	-

*Median baseline SARS-CoV-2 RNA nasopharyngeal viral load was 6.2 log copies/mL.


There was no difference between arms in time-weighted average change in nasopharyngeal viral loads from baseline up to day 7.

No deaths occurred in either arm by day 28.

\rightarrow Remdesivir reduced hospital admission/death by 87%.

Gottlieb RL, et al. N Engl J Med. Dec 22, 2021.


Molnupiravir: MOVe-OUT RCT showed promising results



\rightarrow Molnupiravir reduced the risk of hospitalization/death by 50%.

Caraco Y et al. 31st ECCMID July 9-12 2021 P#4700; MSD Press release October 1st 2021; Bernal AJ et al, N Engl J Med. Dec 16, 2021; doi: 10.1056/NEJMoa2116044.

Molnupiravir: MOVe-OUT RCT showed promising results



Bernal AJ et al, N Engl J Med. Dec 16, 2021; doi: 10.1056/NEJMoa2116044.

Oral Nirmatrelvir/ritonavir (Paxlovid) – Phase 2/3 EPIC-HR

- EPIC-HR (<u>E</u>valuation of <u>P</u>rotease <u>I</u>nhibition for <u>C</u>OVID-19 in <u>H</u>igh-<u>R</u>isk Patients) is a multinational randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.
- 2,246 eligible participants with at least one underlying medical condition and a mild/moderate confirmed diagnosis of SARS-CoV-2 infection (within 5 days) were randomized (1:1) to receive nirmatrelvir/ritonavir or placebo orally every 12 hours for 5 days.
- The primary efficacy endpoint was composite COVID-19 hospitalization or all-cause death by day 28.
- The study was stopped after the first interim analysis with 1,219 adults enrolled by September 29, 2021 was performed.

At 28 days	Nirmatrelvir N=1,039	Placebo N=1,046	<i>P</i> -value
- Hospitalization/death	0.8%	6.3%	<0.001
- Death	No deaths	12 deaths	-
- D/C due to TRAEs	2.1%	4.2%	-

 \rightarrow PF07321332/ritonavir reduced hospital admission/death by 87%. A Phase 2/3 EPIC-SR (<u>Standard-Risk Patients</u>) RCT started in August 2021.

> https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate Pfizer press releases, November 5th & December 14th 2021

Activity of neutralizing monoclonal antibodies and convalescent plasma against Omicron

The Omicron variant is resistant to most neutralizing monoclonal antibodies under EUA except Sotrovimab

Fold reducing neutralizing susceptibility to neutralizing antibodies under EUA

\$	BAM ≑	ETE \$	BAM/ETE \$	CAS \$	IMD \$	CAS/IMD \$	CIL \$	TIX \$	CIL/TIX	SOT \$	REG \$
Alpha	1 ₁₁	16 ₉	1.2 4	1 ₁₇	0.6 17	1 ₈	1.0 ₆	1.7 ₅	0.8 ₄	3* ₁₃	1.4
Beta	>100 ₁₃	>100 ₁₁	>100 ₅	70 ₂₁	0.6 ₂₀	1.3 ₁₁	1 ₅	6.3 ₅	1.3 ₄	1 ₁₂	27 2
Gamma	>100 ₉	>100 ₉	>100	>100 15	0.4 ₁₄	1 5	0.5 ₅	6.4 ₄	0.7	1.2 ₁₀	81 ₂
Delta	>100 10	0.6 ₁₀	1 ₂	0.8 10	1.5 ₁₀	1 ₃	3.5 ₂	1.3 ₂	0.6	1.2 ₆	54 ₂
Omicron	>100 4	>100 ₃	>100	>100 4	>100 4	>100 ₃	>100 4	>100 4	>100 ₂	34	>100

Monoclonal antibody (mAb) abbreviations: BAM: Bamlanivimab/LY-CoV555, CAS: Casirivimab/REGN10933, IMD: Imdevimab/REGN10987, CAS/IMD: Casirivimab+imdevimab/REGN-COV2, ETE: Etesevimab/LY-CoV016/JS016/CB6, CIL: Cilgavimab/COV2-2130/AZD1061, TIX: Tixagevimab/COV2-2196/AZD8895, TIX/CIL: Tixagevimab+Cilgavimab, BAM/ETE: Bamlanivimab+Etesevimab, SOT: Sotrovimab/Vir-7831/S309, REG: Regdanvimab/CT-P59.




Stanford University CORONAVIRUS ANTIVIRAL & RESISTANCE DATABASE

A Stanford HIVDB team website. Last updated on 12/25/2021, 8:52:45 PM.

https://covdb.stanford.edu/page/susceptibility-data/; December 27th 2021

Casirivimab & Imdevimab Reduced 28-day Mortality in <u>Hospitalized</u> Baseline Seronegative Patients: RECOVERY RCT


- Randomized, controlled, open-label platform trial. Eligible and consenting patients were randomly allocated (1:1) to either usual SoC (usual care group) or usual care plus a single dose of REGEN-COV 8g (casirivimab 4g and imdevimab 4g) by IV infusion (REGEN-COV group).
- Primary endpoint was **28-day mortality** assessed first among patients without detectable antibodies to SARS-CoV-2 at randomisation (seronegative) and then in the overall population.
- Between 18 September 2020 and 22 May 2021, **9785 patients were randomly allocated to receive usual care plus REGEN-COV or usual care alone**, including 3153 (32%) seronegative patients 5272 (54%) seropositive patients and 1360 (14%) patients with unknown baseline antibody status.



... Mortality increased in seropositives!

RECOVERY RCT. medRxiv June 16, 2021 (NCT04381936)

Monoclonal Antibodies (mAbs) in <u>Non-Hospitalized</u> Patients Early Treatment in Patients with High Risk of Progression



* 452 patients were assigned to receive a single IV infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo


Chen P et al. NEJM Oct 28 2020; Weinreich DM et al. NEJM, Sep 29 2021; Dougan M et al. NEJM July 14, 2021; Gupta A et al. NEJM Oct 27, 2021.

^{** 266} patients received a single IV infusion of 2,400 milligrams casirivimab and imdevimab (1,200 mg of each), 267 received 8,000 mg casirivimab and imdevimab (4,000 mg of each), and 266 received a placebo, within three days of obtaining a positive SARS-CoV-2 viral test.

^{*** 1,035} patients were randomized to a single IV infusion of either a neutralizing monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory SARS-CoV-2 infection. **** Single IV infusion of 500 mg or placebo. Sotrovimab has a double mechanism of action: neutralization plus inducing ADCC (NK cells) and ADCP (macrophages).

PEP trials with Monoclonal Antibodies (mABs)

- Randomized, double-blind, placebo-controlled trials for prevention of SARS-COV-2 infection in residents and staff of skilled nursing and assisted living facilities where at least 1 case of SARS-CoV-2 infection had been confirmed in the previous 7 days or in asymptomatic household contacts of people with COVID-19 documented within the previous 4 days and returning home.
- mABs can offer immediate protection for exposed or unvaccinated, partially vaccinated or IS individuals in high risk settings (in contrast to vaccines that take 7-14 days after 2nd dose to offer protection).



*Nursing home residents; **Reduction of SARS-CoV-2 infection, shortened time of viral shedding and shortened time of high viral load (>10⁴ copies/mL) shedding **suggesting a benefit for reduced transmission**.

Lilly press release, January 27, 2021; REGENERON press release, April 12, 2021; Cohen MS et al. JAMA. 2021 Jul 6; 326:46-55.

The Omicron variant is resistant to neutralizing antibodies from convalescent plasma (CP)

\$	CP Studies (#)	CP Samples (#)	CP <3-fold (S) (%)	CP 3-10-fold (I) (%)	CP ≥10-fold (R) (%)		
Alpha	58	2145	81%	12%	1 %		
Beta	65	2353	26%	47%	27%		
Gamma	30	1136	50%	40%	10%		
Delta	19	530	50%	31%	19%		
Omicron	5	103	2%	24%	74%		

Convalescent Plasma (CP)

High rates of Omicron reinfections in patients with previous Alpha & Delta infections!




Stanford University CORONAVIRUS ANTIVIRAL & RESISTANCE DATABASE

A Stanford HIVDB team website. Last updated on 12/25/2021, 8:52:45 PM.

https://covdb.stanford.edu/page/susceptibility-data/; December 27th 2021

It is not expected any loss of activity of anti-inflammatory or anticoagulant drugs, so these treatments should not be modified.




COVID-19 Pandemic Update: The Omicron wave!

- Current epidemiology
- Virological characteristics
- Diagnosis
- Clinical manifestations and disease severity
- Efficacy of antivirals and anti-inflammatory drugs
- Vaccines efficacy and boosters
- Take-home messages


January 28th 2022

Waning Immunity: Vaccine efficacy against Delta in the months following the second dose



Mallapaty S et al. Nature. December 2021; 600:580-583.


Waning antibody responses in individuals vaccinated with Pfizer-BioNTech vaccine is more pronounced at 6 mo. and in those over 60 years of age



Naaber P et al. The Lancet Regional Health - Europe. 6 September 6 2021.

The effects of waning antibodies neutralization titer on clinical outcomes: SARS-CoV-2 infection increased regardless age


A SARS-CoV-2 Infection



Most infections were due to the Delta variant

Goldberg Y et al., NEJM October 27, 2021.

The effects of waning antibodies neutralization titer on clinical outcomes: Severe COVID-19 mainly diagnosed ≥60 yr.




Most infections were due to the Delta variant

Goldberg Y et al., NEJM October 27, 2021.


Immunosuppressed patients have a much worse immune response to COVID-19 vaccines than healthy individuals

Percent of subjects with antibody response after <u>two</u> mRNA vaccine doses by immunocompromising condition and study (n=63)



Oliver S. ACIP Meeting. July 22, 2021. https://www.cdc.gov/coronavirus.


BNT162b2 & ChAdOx1 nCoV-19 vaccine efficacy against <u>Delta variant</u> after the 2nd dose



 Fully vaccinated individuals with breakthrough Delta infections have peak viral load similar to unvaccinated cases and can efficiently transmit infection in household settings, including to fully vaccinated contacts, although they have an accelerated viral clearance.

Lopez-Bernal J et al. N Engl J Med. August 12, 2021; 385:585-594; Singanayagam A et al,. Lancet Infect Dis. October 28, 2021.


Neutralization of the Delta Variant Increased with a 3rd mRNA BNT162b2 Vaccine Dose regardless Age



GMFR = Geometric mean fold rises in titers

Falsey AR et al., N Engl J Med. Oct 21 2021; 385:1627-1629.

BNT162b2 & ChAdOx1 nCoV-19 vaccine efficacy against <u>Omicron variant</u> after the 1st, 2nd & 3rd doses




Andrews N, Lopez-Bernal J et al. medRxiv, December 14th 2021

*Boosting with Pfizer (BNT162b2)


Vaccine effectiveness against Omicron symptomatic disease after the booster dose according to the type of vaccination

Two doses of Astra-Zeneca with a Pfizer or Moderna booster dose



UKHSA. Technical briefing #33. December 23, 2021.

Vaccine effectiveness against Omicron symptomatic disease after the booster dose according to the type of vaccination



UKHSA. Technical briefing #33. December 23, 2021.


Vaccine effectiveness against Omicron symptomatic disease after the booster dose according to the type of vaccination

Primary vaccination	Booster	Efficacy at 2-4-wk	Efficacy at +10-wk			
- Astra-Zeneca	Pfizer	60%	35%			
- Astra-Zeneca	Moderna	60%	45%			
- Pfizer	Pfizer	70%	45%			
- Pfizer	Moderna	70%	70%* 🔶			
	Booster wanes at 10 weeks? Will we need additional boosts?					

*Efficacy at 5-9 weeks


UKHSA. Technical briefing #33. December 23, 2021.

Risk of dying from COVID-19 per 10,000 cases by Age, Sex and Vaccination status in Australia - January 2022 – Omicron 90%



http://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-26-january-2022

The new generation of SARS-CoV-2 vaccines must include VoC mutations: The Dream Vaccine




Cohen J. Science. 2021; 372: 227-231; Mallapaty S et al. Nature. December 2021; 600:580-583.

What plan do we have for Omicron?: Vaccination plus Facial Masks, Hand Washing, Social Distance & Non-Pharmacological Prevention Measures!



Rail commuters wearing white protective masks, one with the additional message "wear a mask or go to jail," during the 1918 influenza pandemic in California. Vintage Space/Alamy

https://www.nytimes.com/2020/08/03/us/mask-protests-1918.html



COVID-19 Pandemic Update: The Omicron wave!

- Current epidemiology
- Virological characteristics
- Diagnosis
- Clinical manifestations and disease severity
- Efficacy of antivirals and anti-inflammatory drugs
- Vaccines efficacy and boosters
- Take-home messages

January 28th 2022

Take-home messages

The Omicron variant is spreading very fast World wide (100 countries) replacing Delta variant in one month once introduced in a given country.


Omicron has more than 50 mutations, 36 in the Spike, which give it the highest transmissibility seen ever ($R_0 = 10$).

Omicron also infects vaccinated and previously infected persons. It is not known whether the disease is more serious than that caused by other SARS-CoV-2 variants.

Antiviral drugs maintain activity against Omicron. However, most monoclonal antibodies under EUA are ineffective except for Sotrobimab.

The efficacy of a full vaccination regimen is very low at 6 months. A third dose of a mRNA vaccine increases Omicron disease protection to 70%, although immunity wanes rapidly.

Non-pharmacological prevention measures urgently need to be implemented to mitigate the expansion of Omicron and avoid collapse of the healthcare system.



Acknowledgements

- J. Alcami J. Blanco M. Campins S. de San José O. Coll G. Mora A. Moreno
- R. Paredes
- D. Podzamczer
- C. Pontes
- M. Sans
- A. Sarukhan
- A. Vilella

A. Vallano

- To all front-line health-care workers To our patients and their families

Jan 28th 2022